One-year remission of therapy-resistant SLE after a single course with the bispecific CD3: BCMA antibody teclistamab, but induction of a non-infectious Crohn's-like inflammatory bowel disease.

IF 20.3 1区医学 Q1 RHEUMATOLOGY

Annals of the Rheumatic Diseases Pub Date : 2025-07-01 Epub Date: 2025-05-30 DOI:10.1016/j.ard.2025.05.007

Hanns-Martin Lorenz, Wolfgang Merkt, Juliane Brandt, Thomas Giese, Tarik Exner, Norbert Blank, Margarida Souto-Carneiro, Annika Gauss, Marc S Raab

引用次数: 0

查看原文本刊更多论文

双特异性CD3: BCMA抗体teclistamab单疗程后治疗抵抗性SLE一年缓解，但诱导非感染性克罗恩样炎症性肠病。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Annals of the Rheumatic Diseases 医学-风湿病学

CiteScore

35.00

自引率

9.90%

发文量

3728

审稿时长

1.4 months

期刊介绍： Annals of the Rheumatic Diseases (ARD) is an international peer-reviewed journal covering all aspects of rheumatology, which includes the full spectrum of musculoskeletal conditions, arthritic disease, and connective tissue disorders. ARD publishes basic, clinical, and translational scientific research, including the most important recommendations for the management of various conditions.